SC 13G

                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                  SCHEDULE 13G
                                  Rule 13d-102

                    Under the Securities Exchange Act of 1934
                               (Amendment No.  )*

			   Interleukin Genetics Inc
--------------------------------------------------------------------------------
                                (Name of Issuer)

				Common Stock
--------------------------------------------------------------------------------
                         (Title of Class of Securities)

				458738101
--------------------------------------------------------------------------------
                                 (CUSIP Number)

				  10/21/02
--------------------------------------------------------------------------------
             (Date of Event which Requires Filing of this Statement)

      Check the appropriate box to designate the rule pursuant to which
this Schedule is filed:
                               |_| Rule 13d-1 (b)
                               |x| Rule 13d-1 (c)
                               |_| Rule 13d-1 (d)

----------
*     The remainder of this cover page shall be filled out for a
reporting
person's initial filing on this form with respect to the subject class
of
securities, and for any subsequent amendment containing information
which
would alter disclosures provided in a prior cover page.

      The information required on the remainder of this cover page
shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that
section of
the Act but shall be subject to all other provisions of the Act
(however, see
the Notes).



CUSIP No. 458738101                     13G                       Page
2 of 2
--------------------------------------------------------------------------------
1   NAME OF REPORTING PERSON
    S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

	Valor Capital Management, L.P.    13-3886687
--------------------------------------------------------------------------------
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) |_|

(b) |x|
--------------------------------------------------------------------------------
3   SEC USE ONLY


--------------------------------------------------------------------------------
4   CITIZENSHIP OR PLACE OF ORGANIZATION

   	USA
--------------------------------------------------------------------------------
                  5    SOLE VOTING POWER

                       1,508,075

--------------------------------------------------------------
  NUMBER OF       6    SHARED VOTING POWER
    SHARES
 BENEFICIALLY
   OWNED BY
--------------------------------------------------------------
     EACH         7    SOLE DISPOSITIVE POWER
  REPORTING
    PERSON             1,508,075
     WITH
--------------------------------------------------------------
                  8    SHARED DISPOSITIVE POWER


--------------------------------------------------------------------------------
9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    	1,508,075
--------------------------------------------------------------------------------
10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES*


|_|
--------------------------------------------------------------------------------
11  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

	7.2%
--------------------------------------------------------------------------------
12  TYPE OF REPORTING PERSON*

	PN
--------------------------------------------------------------------------------
                     *SEE INSTRUCTIONS BEFORE FILLING OUT

Item 1.
(a) The name of the issuer is Interleukin Genetics Inc ("The Issuer")
(b) The principal executive office is located at 135 Beaver Street,
    2nd floor, Waltham, MA 02452

Item 2.
(a)  The names of the persons filing this statement ("the statement")
     are Valor Capital Management, L.P., a Delaware limited partnership
     ("Valor Capital")
(b)  The Principal Business Office of the Filers is 137 Rowayton Ave.,
     Rowayton, CT 06853
(c)  For citizenship information see item 4 of the cover sheet
     of each Filer
(d)  This Statement relates to the Common Stock, $.001 par value
     of the Issuer
(e)  The CUSIP Number of the common stock of the Issuer
     is 458738101

Item 3. If this statement is filed pursuant to "240.13d-1(b),
      or (c), check whether the person filing is a:
(a)  _ Broker or dealer registered under section 15 of the Act
       (15 U.S.C. 78c)
(b)  _ Bank as defined in section 3 (a)(6) of the Act (15 U.S.C. 78c)
(c)  _ Insurance company as defined in section 3(a)(19) of the Act
       (15 U.S.C.78c)
(d)  _ Investment company registered under section 8 of the Investment
Company
       Act of 1940 (15 U.S.C. 80a-8).
(e)  _ An Investment adviser in accordance with "240.13d-1(b)(1)(ii)(E)
(f)  _ An employee benefit plan or endowment fund in accordance with
       "240.13d-1(b)(1)(ii)(F)
(g)  _ A parent holding company or control person in accordance with
       "240.13d-1(b)(1)(ii)(G)
(h)  _ A savings associations as defined in Section 3(b) of the Federal
       Deposit Insurance Act (12 U.S.C. 1813)
(i)  _ A church plan that is excluded from the definition of an
       investment company under section 3(c)(14) of the Investment
       Company Act of 1940 (15 U.S.C. 80a-3)
(j)  _ Group, in accordance with "240.13d-1(b)(1(ii)(J)


Item 4. Owwnership.
See Items 5-9 and 11 on the cover page for each filer.

Item 5. Ownership of Five Percent or Less of a Class.
     If this statement is being filed to report the fact that as of the
     date hereof the reporting person has ceased to be the beneficial
     owner of more than five percent of the class of securities,
     check the following _.
 Instruction: Dissolution of a group requires a response to this item.

Item 6. Ownership of More than Five Percent on Behalf of Another
Person.
     If any other person is known to have the right to receive or the
power
     to direct the receipt of dividends from, or the proceeds from the
     sale of, such securities, a statement to that effect should be
     included in response to this item and, if such interest
     relates to more than five percent of the class, such person
     should be identified.  A listing of the shareholders of
     an investment company registered under the Investment
     Company Act of 1940 or the beneficiaries of employee
     benefit plan, pension fund or endowment fund is not required.

Item 7. Identification and Classification of the Subsidiary Which
        Acquired the Security Being Reported on by the Parent Holding
        Company.
     If a parent holding company or control person has filed this
     schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under
     Item 3(g) and attach and exhibit stating the identity and the
     Item 3 classification of the relavant subsidiary.  If a
     parent holding company or control person has filed this
     schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d),
     attach an exhibit stating the identification of the relavant
     subsidiary.

     John M. Kratky III is the managing member and control person of
     KM.  KM is the general partner and control person of Valor
Capital.
     Valor Capital is an investment vehicle formed for the purpose
     of investing and trading in a wide variety of securities and
financial
     instruments.
     _ Exhibit attached

Item 8. Identification and classification of the Members of the Group
     If a group has filed this schedule pursuant to Rule
13d-1(b)(1)(ii)(J)
     so indicate under Item 3(j) and attach an exhibit stating the
identity
     and Item 3 classification of each member of the group.  If a group
     has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d)
     attach an exhibit stating the identity of each member of the
group.

Item 9. Notice of Dissolution of Group
     Notice of dissolution of a group may be furnished as an exhibit
     stating the date of the dissolution and that all further filings
     with respect to transactions in the security reported on will
     be filed, if required, by members of the group, in their
     individual capacity.  See Item 5.
     _ Exhibit attached

Item 10. Certification
(a)  The following certification shall be included if the statement
     filed pursuant to "240.13d-1(b):

     By signing below I certify that, to the best of my knowledge and
     belief, the securities referred to above were acquired and are
     held in the ordinary course of business and were not acquired and
     are not held for the purpose of or with the effect of changing
     or influencing the control of the issuer of the securities and
     were not acquired and are not held in connection with or as a
     participant in any transaction having that purpose or effect.

     The following certification shall be included if the statement
filed
     pursuant to "240.13d-1(c)":

(b)  By signing below I certify that, to the best of my knowledge and
     belief, the securities referred to above were not acquired
     and are not held for the purpose of or with the effect of changing
     or influencing the control of the issuer of the securities and
were
     not acquired and are not held in connection with or as a
participant
     in any transaction having that purpose or effect.


				Signature

After reasonable inquiry and to the best of my knowledge and belief,
I certify that the information set forth in this statement is
true, complete and correct.

Dated October 21, 2002

					_____________________________
					John M. Kratky III

					Valor Capital Management, LP


					By: Kratky Management, LLC
					    General Partner

					____________________________
                                        John M. Kratky III,
					Managing Member